Opportunity Overview
The Maine Department of Health and Human Services, Office of Behavioral Health, maintains a current Willing & Qualified contracting pathway whose State table and PJF header are labeled Immunization Program, but whose controlling service narrative and attached provider schedule identify the actual service as Xylazine Wound Care — SFY26. The current contracts run through September 30, 2026.
Service Scope
The providers deliver wound care, other clinical services, clinical advice, and referrals for people who inject drugs and experience xylazine-related or other injection-related ailments. Services are delivered on-site at syringe service programs and through outreach to populations disproportionately affected by injection drug use.
Current Funding and Providers
The PJF lists $472,204 in current contracting value. The attached schedule identifies City of Portland at $252,204 and Family Planning Association of Maine at $220,000. These organizations are treated as incumbents for this exact pathway.
Source-Data Quality Warning
The State procurement table and PJF Part I call this service “Immunization Program,” while Part III describes xylazine-related wound care and the attached provider schedule explicitly labels the service “Xylazine Wound Care- SFY26.” Atlas therefore uses the detailed service description and attachment as the canonical program identity and preserves the State labeling inconsistency rather than publishing this as a broad immunization opportunity.
Eligibility and Expansion
The State says the selected providers have existing relationships with syringe service programs, familiarity with the target population, and experience from similar Maine CDC work. DHHS states that it does not intend a competitive procurement at this time, but would consider another contract if another provider expresses interest. Additional funding or a contract is not guaranteed.
Atlas Relevance
This is a legitimate public-health and harm-reduction pathway involving clinical wound-care services and outreach. The current record does not establish remote-exam technology, telehealth infrastructure, diagnostic-device, or N9+ costs as allowable, so those costs should not be inferred without written DHHS confirmation.
Dr. Miltie does not appear to be a viable direct prime provider on the current record because provider suitability depends on direct wound-care clinical capability, an established syringe-service-program relationship, familiarity with the target population, and DHHS acceptance.
Next Action
Preserve City of Portland and Family Planning Association of Maine as incumbents. For any prospective additional provider, verify current W&Q availability, clinical wound-care qualifications, syringe-service-program relationship, target-population experience, service geography, funding availability, and the controlling service identity with DHHS before applying canonical CRM, Atlas_Email_Queue, Email Opt-Out, sent-history, reply, bounce, deadline, approval, and exact-opportunity deduplication controls.
Official source: Maine Division of Procurement Services, CT NOI 1020250909. Source labeling note: the State header says “Immunization Program,” while the detailed narrative and attachment identify Xylazine Wound Care.